Decoding multiple sclerosis: linking autoimmunity, and nutrition/environmental factors to mitochondrial dysfunction and therapeutic opportunities

Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination

Multiple sclerosis (MS) has conventionally been considered a prototypical autoimmune disorder. While modern immunotherapies effectively control relapsing conditions, they fail to avert progressive neuroinflammation, neurodegeneration, and remyelination failure. This review offers an evidence-based recontextualization....

ALS: An Organism-Wide Bioenergetic Failure Due to Mitochondrial Dysfunctions?

Amyotrophic lateral sclerosis (ALS) is a devastating and invariably fatal disease for which currently available disease-modifying therapies provide only modest benefit. Defining its underlying pathogenesis is therefore essential for the development of effective treatments. Increasing evidence indicates that ALS is not...

Advancement and Challenges in Multiple Sclerosis: Understanding the Disease from Etiology to Treatment.

Multiple Sclerosis (MS) is a chronic immune-mediated neurodegenerative disorder of the Central Nervous System (CNS) that affects more than 2.8 million people worldwide. It is recognized as one of the leading causes of non-traumatic neurological disability among young adults. It is an inflammatory demyelination disease...

Diabetes and the Nervous System: Linking Peripheral Neuropathy to Central Neurodegeneration.

Diabetes mellitus affects both the peripheral and central nervous systems, giving rise to a spectrum of neurological complications that extend far beyond the traditional focus on diabetic peripheral neuropathy (DPN). Chronic hyperglycemia disrupts cellular homeostasis through increased formation of advanced glycation e...

Characterization of myelin lipid changes across disease stages in experimental autoimmune encephalomyelitis 2302268

Novel insights are provided into the dynamics of the CNS lipidome during neuroinflammation and suggest that myelin lipid alterations could contribute to MS progression through mechanisms independent of neuroinflammation.

The gut microbiota-miRNA axis in multiple sclerosis: Mechanisms and therapeutic potentials.